Find clinical trials for Chronic Lymphocytic Leukemia in London, England
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near London, England, GBR:
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...
Phase 1, Phase 2
London, United Kingdom and 11 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
London, United Kingdom and 111 other locations
This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in c...
Phase 1
London, United Kingdom and 10 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
London, United Kingdom and 130 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
London, London, City Of, United Kingdom and 143 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
London, London, City Of, United Kingdom and 179 other locations
) and prednisone).The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic...
Phase 1, Phase 2
London, United Kingdom and 75 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Romford, United Kingdom and 86 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
London, Greater London, United Kingdom and 231 other locations
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...
Phase 1, Phase 2
London, United Kingdom and 48 other locations
Clinical trials
Research sites
Resources
Legal